FDA
-
-
-
-
-
-
-
BioVie to Present New Bezisterim Findings in Parkinson’s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting
-
-
-
-
-
-
-
BioVie to discuss Phase 2 Long Covid trial results in conference call
-
-
-
-
-
-
-
BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease
-
-
-
-
-
-
-
BioVie to host virtual event on bezisterim Parkinson's treatment
-
-
-
-
-
-
-
BioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual Meeting
-
-
-
-
-
-
-
BioVie presents Long COVID trial design at medical symposium
-
-
-
-
-
-
-
BioVie presents data on bezisterim's biological aging effects
-
335,309 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


